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A STUDY ON SERUM CHOLINESTERASE AS 
A BIOMARKER OF LIVER CIRRHOSIS 
 
ABSTRACT 
Background : Serum Cholinesterase is an enzyme which is synthesized 
by the liver and its level reflects the liver synthetic function . 
Methods : Among patients with liver cirrhosis, liver function tests like 
serum albumin, serum bilirubin,PT INR and serum cholinesterase were done 
within a week of enrolment.100 patients of liver cirrhosis were studied. The 
correlation between serum cholinesterase levels and serum albumin, bilirubin, 
INR, child pugh class and MELD score was studied.  
Results: Mean serum cholinesterase levels in Child Pugh class A was 
4692.25, B was 2779.68, C was 1892.11. The correlation coefficient between 
serum cholinesterase and albumin was 0.52, -0.675 with serum bilirubin, -0.49 
with INR, -0.85 with Child Pugh class, -0.79 with MELD score, (p<0.01). 
Conclusions: Serum cholinesterase shows good correlation with serum 
albumin, serum bilirubin, PT INR, Child Pugh and MELD score. It helps both 
in the diagnosis of liver cirrhosis and assessing its prognosis. 
Keywords: Liver cirrhosis, Serum cholinesterase, serum albumin, serum 
bilirubin, PT INR, Child Pugh class, MELD score. 
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INTRODUCTION 
Hepatic cirrhosis is a commonly encountered clinical entity. Its 
management includes an array of tests like serum albumin levels, PT 
INR, serum bilirubin, aminotransferases. Various classification systems 
have also been developed including the MELD and Child Pugh scores for 
assessing its severity and prognosis. However, the routinely used tests 
have certain shortcomings: 
• Serum albumin - maybe abnormal due to extrahepatic causes  like 
intestinal malabsorptive states, malnutrition, renal pathologies and 
secondary to albumin transfusions, thereby interfering with its 
usage as a marker of liver synthetic capacity and severity of 
cirrhosis. 
• PT INR – abnormal values may occur secondary to vitamin K 
deficiency, therapeutic anticoagulation, congenital clotting factor 
deficiencies and its values are altered following fresh frozen 
plasma transfusions in the treatment of coagulopathy which occurs 
in decompensated liver disease. 
• Serum bilirubin – raised in hemolysis, extrahepatic causes. 
• Serum ALP – altered in disoreders of placenta, bone, intestinal 
mucosa.  
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• Similarly, aminotransferase, LDH levels can be abnormal 
secondary to their release from extrahepatic sources following cell 
membrane damage. 
In this regard, serum cholinesterase has been studied as a test of 
liver function since the early 1950s. It was found that the source of serum 
cholinesterase is the liver and hence reflects the hepatic function. It can 
overcome some of the shortcomings of the commonly measured tests of 
liver function. For instance its values are not affected by albumin or fresh 
frozen plasma transfusions. 
A lot of studies have shown that it helps both in diagnosing liver 
cirrhosis, in the assessment of its severity and prognosis. 
Studies have also shown that it shows good correlation with the 
routinely performed tests of liver function like serum albumin, PT INR, 
Child Pugh and MELD scores.     
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AIMS & OBJECTIVES 
 
 To estimate the level of serum cholinesterase in patients with 
liver cirrhosis 
 
 To compare its level with other tests of liver function like serum 
albumin, serum bilirubin, PT INR, MELD and Child Pugh 
scoring. 
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REVIEW OF LITERATURE 
In 1940 McArdle found that values of serum cholinesterase were 
very low in patients with liver disease. (5) 
  In 1952 Andrew Wilson et al reported that the serum cholinesterase 
values varied significantly in those with liver disease compared with 
normal subjects and those recovering from liver disease. 
They also observed that estimation of serum cholinesterase levels 
was useful in assessing  the liver function recovery , as values returned to 
normal during recovery.(4) 
In 1960 R.G.O. Kekwick noted that the serum cholinesterase 
values were always very low in chronic liver disease, though the same 
could not be said of acute liver disease. (3) 
CIRRHOSIS OF LIVER 
It is a histopathological condition of distortion of the architecture 
of liver along with regenerative nodule formation. As a consequence 
there is reduction in the liver mass and liver functions are affected and 
blood flow inside the liver is affected. This is due to the activation of the 
stellate cells in the liver leading to deposition of extracellular matrix 
tissue and collagen. 
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Though initially cirrhosis was considered to be an irreversible 
process, it has now been shown that in some instances that when the 
primary insult leading to cirrhosis is removed, the fibrosis can undergo 
reversal. 
Typical examples include : 
Successful treatment – chronic hepatitis C, hemochromatosis 
Discontinuation of alcohol use in those with alcoholic liver disease. (2) 
BRIEF HISTORY 
In 1761 – Gianbattista Morgagni ,the father of anatomic pathology, 
noted the liver abnormality in the publication of the compliation of his 
autopsies   
In 1826- Laennec gave the term of cirrhosis, meaning orange 
colour in greek,due to the colour of the liver in cirrhosis.(1) 
In 1930-Rossele gave the first theory of pathogenesis of cirrhosis- 
 
 
 
 
       Parenchymal degeneration  
                      Scarring  
       Parenchymal regeneration 
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Normal microscopic anatomy of liver 
 
The functional unit of the liver is – the acinus 
It is roughly triangular in shape. At the base lies the branches of 
portal vein, bile duct and branches of hepatic artery. This constitutes the 
Portal triad. At the apex of the acinus lies the terminal hepatic vein.  
Zones of the liver parenchyma: 
Zone 1 - adjacent to the portal vein 
Zone 2-is intermediate zone 
Zone 3-adjacent to the terminal hepatic vein 
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Cords of hepatocytes are radially oriented around the terminal hepatic 
vein. Vascular sinusoids are present between these cords. 
Fenestrated endothelial cells line these sinusoids and form the space of 
Disse. 
Kupffer cells – belonging to the mononuclear phagocyte family are found 
in this space. 
Stellate cells-involved in vitamin A metabolism are found scattered in 
this space. These are responsible for forming collagen by undergoing 
transformation into myofibroblast whenever there is liver inflammation.  
PATHOGENESIS OF CIRRHOSIS 
Normal liver contains type I and type III collagens distributed 
mainly around the central veins and portal tracts. And type IV collagen 
forms delicate strands in the space of Disse. 
In Cirrhosis- there is lobular deposition of types I and III collagen 
resulting in septae formation .vascular channels are formed in these 
septae resulting in blood shunting around liver parenchyma.  
Collagen gets deposited in the space of Disse continuously  
fenestrations in the endothelial sinusoidal cells are lost  the sinusoidal 
space no longer serves as a channel in the exchange of solutes between 
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the plasma and hepatocytes. And the secretion of albumin, coagulation 
factors by the liver is affected. 
Biliary channels  get obliterated  jaundice   
Chronic inflammation Activation of  Kupffer cells  cytokine 
secretion  activation of stellate cells  formation of extracellular 
matrix , collagen deposition.   
Perisinusoidal stellate cells  acquire myofibrils  vascular resistance 
in the liver increases. 
Hepatocytes which remain  regenerate  formation of spherical 
nodules (6) 
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Gross appearance of normal liver 
 
 
Cirrhotic liver 
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Thus, Cirrhosis is characterized by: 
1. Fibrous septa bridging the portal tracts and the hepatic veins 
2. Regenerating nodules surrounded by fibrosis –may be micronodular  
     (<3 mm) or macronodular 
3. Architectural disruption of the liver 
CAUSES OF CIRRHOSIS 
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Clinical features of cirrhosis(1) 
1. Non specific: anorexia ,wasting , easy fatiguability 
2. Jaundice 
3.Hyperdynamic circulation- flushed peripheries, bounding pulse,  
   increased portal blood flow, decreased renal blood flow 
4. Skin changes- 
 
spider nevi 
 
palmar erythema 
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white nails 
5.Clubbing of fingers 
6.Endocrine abnormalities: 
Hypogonadism   decreased potency, libido,atrophic testes 
Gynaecomastia 
7.Enlargement of the parotids(alcoholics) 
8.Foetor hepaticus 
9.Peripheral oedema,Ascitis 
10.Bleeding from the GIT 
11.Sleep disturbances with or without alterations in the sensorium 
12.Hepatic flaps 
13.Splenomegaly  
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Clinical features 
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COMPLICATIONS OF CIRRHOSIS 
 
PORTAL HYPERTENSION 
It is hepatic venous pressure gradient of more than 5 mmhg. 
It is due to : 
1.Raised intrahepatic resistance to the flow of blood and 
2.Vasodilation  increase in the splanchnic  blood flow            
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Pathogenesis of portal hypertension 
 
 
 
PHT
leads to
gastroesophageal 
varices
ascitis hypersplenism
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Gastroesophageal varices: 
About  5- 15% of patients with cirrhosis per year  develop varices 
1/3 rd of those with varices  bleed 
The porto-systemic collaterals 
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Porto – systemic anastamotic sites in cirrhosis: 
 
Factors which predict the risk of bleeding are: 
1. Cirrhosis severity as measured by CHILD PUGH score and MELD 
score 
2. Wedged hepatic vein pressure 
3. varix size 
4. varix location 
5. endoscopic stigmata- red wale signs, bluish colour, hematocystic 
spots, etc. 
6. tense ascitis. 
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Treatment: 
1.Primary prophylaxis: 
• Involves endoscopic screening  identification of varices at risk of 
bleeding  band ligation of varices or use of non selective beta 
blockers 
2.Treatment of acute bleed :  
• replacement of blood /fluid 
• use of stomatostatin and octreotide (50-100 micrograms/hr 
infusion) 
• balloon tamponade using Sengstaken-Blakemore tube/Minnesota 
tube 
• endoscopy - band ligation of varices or sclerotherapy to control 
acute bleed 
• Prevention of further bleed with EVL 
3. In patients with variceal hemorrhage which is recurrent treatment 
involves:  
• endoscopic +/-  pharmacologic therapy, and once control of bleed 
is achieved patients with Child’s class A can be considered for 
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surgical shunt or TIPS. And patients with Child’s class B or C 
should be evaluated for transplant, and TIPS should be considered. 
ASCITIS 
It is the collection of fluid within the peritoneal cavity. The most 
common cause is cirrhosis due to portal hypertension. 
Pathogenesis: 
• Cirrhosis  increased intrahepatic resistanceincreased portal 
pressure  
• Increased nitric oxide Splanchnic arterial vasodilation 
increased portal venous inflow 
Both lead to increased splanchnic lymph production   
• Vasodilation  arterial underfilling  renin angiotensin 
aldosterone axis activation  sodium retention  accumulation of 
fluid and extracellular fluid volume expansion   ascitis 
• Synthetic function of liver reduced  hypoalbuminemia  reduced 
oncotic pressure of plasma  leak of fluid into peritoneal cavity 
Clinical features: 
(i) increase in abdominal girth 
(ii) peripheral edema  
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(iii) dyspnoea when ascitis is massive 
(iv) hepatic hydrothorax 
Treatment: 
• dietary sodium restriction <2 g/day 
• diureticsspironolactone 100-200 mg/day upto 400-600 
mg/day,furosemide 40-80 mg/day upto 120-160 mg/day 
• Refractory ascitis is presence of ascitis inspite maximal dose of 
diuretics in patients compliant with a low-sodium diet. 
• repeated large-volume paracentesis 
• TIPS 
Spontaneous bacterial peritonitis 
Infection of the ascitic fluid spontaneously presumably due to 
translocation of the gut florato mesenteric lymph nodes  bacteremia 
ascitic fluid seeding with bacteria 
Most common organisms are : E.coli and other microbial flora. 
Streptococcus viridians, staph.aureus and other gram positive bacteria can 
also be found. 
Presence of  >2 organisms – suggests SBP due to a perforated viscus 
Diagnosis : absolute neutrophil count >250/microliter, cultures 
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Treatment – 2nd generation cephalosporin-cefotaxim 
Prophylaxis against SBP recommended-for patients with UGI bleed,and 
those recovered from a episode of UGI  bleed. 
SPLENOMEGALY AND HYPERSPLENISM 
It’s a complication of portal hypertension. 
Hypersplenism is characterized by leucopenia and thrombocytopenia. 
No specific treatment is required for splenomegaly. 
Splenectomy’s done under very rare circumstances. 
HEPATORENAL SYNDROME 
It is a form of functional renal failure without renal pathology. 
Occurs in 10% of advanced cirrhosis patients. 
There is renal vasoconstriction alongwith reduced systemic vascular 
resistance 
• Type 1 HRS - significant decrease in creatinine clearance within 1-
2 weeks  
• Type 2 HRS -  rise in serum creatinine which is relatively stable 
and has a better outcome than type 1 HRS. 
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Diagnosis – is by exclusion of other etiologies of acute renal failure 
    International ascitis club criteria for HRS: (2007)  
 
Treatment : 
• midodrine, 
• octreotide, 
• intravenous albumin, 
• best treatment being liver transplantation. 
HEPATIC ENCEPHALOPATHY 
Is an alteration in the patient’s mental status and cognitive function 
in the presence of liver failure. 
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There is exposure of brain to neurotoxins due to shunting of gut 
derived neurotoxins along with hepatic insufficiency. Several neurotoxic 
substances may be involved, this includes : 
• ammonia, 
• I3 aminobutyric acid,  
• manganese ,  
• GABA ,  
• mercaptans and  
• short chain fatty acids.(7)   
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The neurologic symptoms can be reversed with the restoration of 
liver function 
Precipitating factors: (8) 
• Sepsis-increase in blood ammonia levels with enhanced effect of 
toxins in CNS  
• Gastrointestinal bleed-liver function impairment with rise in blood 
ammonia levels  
• Hypokalemia, azotemia, increased protein intake, dehydration, 
constipation and diuretics-due to increase in blood ammonia levels 
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• Acute hepatitis-due to further impairment of liver function by 
activated cytokines and cytokines may increase blood brain barrier 
permeability to ammonia. 
• Surgery-due to hepatic hypoperfusion 
• Psychoactive drugs - by activation of inhibitory neurotransmission 
Clinical features: (9) 
• Alterations in consciousness-sleep disturbances in the form of 
hypersomnia initially, with later reversal of normal sleep pattern , 
slowness of responses , apathy, delirium. 
• Personality changes – irritability, lack of concern for others. 
• Intellectual deterioration – visuo spatial disturbances detected as 
constructional apraxia, confusion, difficulty writing. 
• Speech – monotonus with slowness, slurring, dysphasia 
• Fetor hepaticus due to lung excretion of mercaptans. However does 
not have any correlation with the duration or degree of 
encephalopathy. 
• Flapping tremor or asterixis - due to defective inflow of afferent 
information to the reticular formation of brainstem leading to 
lapses in posture. It is demonstrated by outstretching of patients 
arms and separation of fingers or hyperextension of wrists. There is 
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flexion extension movements occurring at the metacarpophalangeal 
joints and wrists alongwith movements of the digits laterally. 
Flapping tremors 
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Treatment : (2) 
1. Treatment of precipitating factors 
2. Lactulose – leads to colonic acidification , catharsis  nitrogenous 
waste product elimination from the gut. Dose titrated to result in 2-3 soft 
stools/day. 
3. Poorly absorbed antibiotics like metronidazole and neomycin. 
4. Rifaximin 550 mg twice daily.   
 5. Zinc supplementation.  
PULMONARY COMPLICATIONS: (10) 
(i) Hepato pulmonary syndrome- vasodilation of pulmonary 
microvasculature  hypoxemia. 
Clinical features: 
Platypnoea- dyspnoea in upright posture due to vasodilation at the 
lung base with blood shunting through the base in the upright 
posturehypoxemia 
Clubbing of the digits, spider angioma and cyanosis. 
Treatment: the only proved treatment is liver transplantation. 
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Intrapulmonary vasodilation occurring in HPS: 
 
(ii) Portopulmonary hypertension- vascular remodeling  
increased pulmonary vascular resistance  raised mean 
pulmonary artery pressure (>25 mm hg) 
Clinical features: 
• Nonspecific. Most common is progressive eexertional dyspnoea, 
syncope, edema of the peripheries, chest pain. 
• JVP maybe raised with a loud second heart sound-pulmonary 
component and a systolic murmur due to tricuspid regurgitation.  
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Treatment of portopulmonary hypertension:  
• Vasodilators (can reverse the vasoconstriction but almost no effect 
on the fibrotic remodeling changes). 
• Diuretics.  
• Prostacyclin (epoprostenol) (64,65,66) -vasodilator and inhibitor of 
platelet aggregation. 
• Bosentan (67, 68), Ambrisentan – endothelin receptor antagonists 
• Inhalation of nitric oxide. 
• L-arginine. 
• Phosphodiesterase inhibitors. (69)   
• Orthotopic liver transplantation – not curative, indicated in only 
selected patients who improve clinically after medical therapy. (70) 
CARDIAC CHANGES IN CIRRHOSIS 
• Circulation is hyperdynamic in patients with liver cirrhosis. 
• Peripheral vascular resistance is reduced and so is arterial BP. 
• Cardiac output is raised. 
• They also have prolonged QTc.(22) 
• Cirrhotic cardiomyopathy characterized by: 
 Systolic dysfunction with 
 ejection fraction in the resting state <55% 
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 reduced increase in cardiac output during exercise, states 
of change in volume or with pharmacologic stress. 
 Diastolic dysfunction with 
 E/A ratio <1.0 (ratio of early to late ventricular filling 
velocity). 
 prolongation of isovolumetric relaxation time and also 
the deceleration time. 
 Electrophysiological changes 
Mechanism of cirrhotic cardiomyopathy:      
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MALNUTRITION : 
Cirrhosis is a catabolic state assosciated with metabolism of muscle 
protein. 
Factors contributing to malnourishment in cirrhotics include 
decreased dietary intake, alterations in protein metabolism and decreased 
nutrient absorption from the GIT. 
Treatment : dietary supplementation. 
COAGULOPATHY: 
Decrease in the synthesis of vitamin K dependent coagulation 
factors, and decreased clearance of anti coagulants 
They may also suffer from thrombocytopenia as a result of 
hypersplenism and abnormalities of platelet function. 
Treatment :  
• Desmopressin – may improve bleeding time and activated partial 
thromboplastin time but does not affect prothrombin time. (71) 
• Vitamin K – to optimize gamma carboxylation of factors 
dependent on vitamin K. (72) 
• Fresh frozen plasma – In cases of bleeding due to clotting factor 
deficiencies. 
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 BONE DISEASE: 
There is increased bone resorption in cirrhotics leading to bone 
loss.  
Treatment: bisphosphonates if there is decreased bone mass in 
DEXA scan. 
HEMATOLOGIC ABNORMALITIES: 
Neutropenia, macrocytosis and anemia due to hypersplenism, iron 
deficiency, hemolysis and deficiency of folate. 
INVESTIGATIONS: 
1. Complete blood count : (11) 
• Leucopenia 
• thrombocytopenia 
• anaemia 
2.PT INR – raised in caogulopathy. 
3.Liver function tests: (12) 
• bilirubinnormal in compensated cirrhosis 
• serum albumindecreased 
• globulinsincreased 
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• reversal of albumin - globulin ratio 
• moderate rise in aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) 
• alkaline phosphate raised-more in primary sclerosing cholangitis 
and primary biliary cirrhosis 
• raised gamma glutamyl transpeptidase (GGT) – alcohol induced 
liver disease 
4. Renal function tests: 
• Serum creatinine - raised in hepato renal syndrome 
• Serum sodium levels- hyponatremia – correlates with disease 
severity 
5. Ultrasound abdomen shows: (13,14) 
• Shrunken liver  
• nodular surface  
• increase in the liver echoes 
6. Fibroscan helps assess the severity of fibrosis 
7. Liver biopsy (15) - has sensitivity of  80-100 %, is the confirmatory 
test. 
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The traditional liver function tests 
Routinely peformed liver function tests include : (50) 
Tests of liver synthetic function: 
1.SERUM ALBUMIN: 
Amount of albumin secreted by the liver per day is around 10 
grams. 
Normal level: 3.5 – 5.0 g/dL  
When there is hepatocellular injury or damage the ability of the 
liver to synthesis albumin is reduced leading to hypoalbuminemia. 
However levels of serum albumin can also be reduced in conditions 
such as :  
• enteropathy,  
• malnutrition,  
• kidney diseases and  
• hormonal disturbances. 
Thus hypoalbuminemia does not necessarily indicate hepatic 
dysfunction. 
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The half life of albumin is around 20 days hence not useful in 
assessing hepatic synthetic function in acute liver disease. 
But it can be used for assessing the prognosis in chronic liver disease. 
Pre albumin is also synthesized by liver but its half life is shorter. 
Several extrahepatic factors influence its levels hence it is not used for 
assessing liver dysfunction. 
2.PROTHROMBIN TIME: 
The liver synthesizes all the clotting factors except factor VIII 
which is synthesized by reticuloendothelial cells and endothelium of the 
vessels. 
Prothrombin time is a measure of the production rate of thrombin 
from prothrombin.    
  This is dependent on factors II, VII, IX, X which are essential for 
thrombin generation. And these are produced in the liver. Thus 
prothrombin time is a measure of hepatocyte synthetic function. 
Normal value – 10.9-12.5 seconds  
 But, prothrombin time can also be increased in the following conditions:
• vitamin K deficiency, 
• therapeutic use of anti coagulants, 
• in states of consumptive coagulopathy like disseminated 
intravascular coagulation, 
• congenital clotting factor deficiencies.
In liver disease when prothrombin time is prolonged, factor VIII 
levels are increased or normal but in DIC, levels of factor VIII are 
reduced. 
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Prothrombin time helps assess the hepatic synthetic function both 
in patients with acute and chronic liver disease. 
The international normalized ratio (INR) has been used to 
standardize anticoagulation therapy monitoring and is used in the MELD 
and Child Pugh scoring systems. 
Normal value 0.9-1.2 
Role of vitamin K: 
It is essential for gamma carboxylation of the clotting factors II, 
VII, IX, X and their normal functioning. 
Vitamin K deficiency can be due to: 
- malnutrition 
- antibiotic usage 
- malabsorptive states 
Use of warfarin affects vitamin K induced gamma carboxylation 
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Tests of hepatocellular necrosis and excretory functioning of liver: 
1. AMINOTRANSFERASES: 
This includes Aspartate aminotransferase (AST,otherwise called 
serum glutamic oxaloacetic transaminase [SGOT] and alanine 
aminotransferase(ALT, otherwise called  serum glutamic pyruvic 
transaminase [SGPT]). 
ALT is predominantly found in the liver, in the cytoplasm. 
But, AST is found in a number of extrahepatic sites like skeletal 
muscle, brain, kidneys, myocardium, pancreas, RBC s, in the cytoplasm 
and mitochondria. 
Values of these enzymes correlate with the body mass index. 
Normal values: 
ALT 10 – 55 U/L 
AST 10 – 40 U/L 
 
  Raised levels of these enzymes suggest hepatocellular injury. 
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In patients with inappropriately elevated AST levels 
(disproportionate to the ALT levels), extrahepatic origin of this enzyme 
must be excluded. 
However, in severe rhabdomyolysis levels of both these enzymes 
are high.  
However, elevated levels of serum aminotransferases correlate 
poorly with severity of liver damage or injury and is also not a good 
predictor of the outcome in liver disease. 
Values can be normal even in patients with advanced liver 
cirrhosis. 
Azotemia can cause a falsely low serum levels of AST.     
AST can also rarely form a complex with albumin leading to 
persistently raised serum AST levels. 
AST/ALT ratio: 
• Alcoholic hepatitis – ratio is >2 
• Cirrhosis secondary to liver disease of any etiology – ratio >1 
• NASH (nonalcoholic steatohepatitis) in the absence of cirrhosis– 
ratio less than or equal to 1   
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• Wilson s disease – may have ratio even graeter than 4 in fulminant 
cases. 
2. LACTATE DEHYDROGENASE: 
Found in a wide variety of tissues like liver, myocardium, RBC s, 
skeletal muscle, kidneys and brain. 
Levels are raised in ischemic hepatitis and in malignant 
infiltrations of liver. 
Markers of cholestasis 
1. ALKALINE PHOSPHATASE: 
Non specific – found in bone, kidney, intestine, WBC s, placenta. 
Half life is 5 - 7 days  
Normal level : 45 – 115 U/L  
Levels are raised in active metabolic states eg.pregnancy, 
adolescence. 
Raised values are also found in the following states: 
• chronic renal failure 
• biliary obstruction 
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• primary liver malignancies 
• liver secondaries 
  “Regan isoenzyme” – ALP levels raised in patients with 
malignancy but without bone/ liver involvement. 
“Bystander phenomenon”- values are raised as a result of non 
specific hepatitis in Hodkin’s disease and renal malignancies but without 
direct liver involvement. 
2.  GAMMA GLUTAMYL TRANSPEPTIDASE(GGTP) : 
It is a microsomal enzyme. 
Found in  hepatocytes, biliary epithelium, kidney, heart, pancreas, 
lung, brain and spleen. 
Normal level : 0 – 30 U/L 
Values are raised in cholestasis and a GGTP/ALP ratio of >2.5 
suggests alcohol use. 
3.  5′-NUCLEOTIDASE (5′NT):    
Found in liver, pancreas, blood vessels, myocardium and brain. 
In liver it is found in canalicular and sinusoidal plasma membranes. 
Normal value: 0 – 11 U/L 
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Values are raised in cholestatic liver disease 
Values lag behind the elevations of GGTP and ALP. 
4. BILIRUBIN 
It is the breakdown product of catabolism of hemoglobin. 
Normal value: 0.0 – 1.0 mg/dL 
Pathway showing generation of bilirubin: 
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Normal value is < 1 mg/dL 
It is fractionated into direct and indirect bilirubin: 
DIRECT BILIRUBIN INDIRECT BILIRUBIN 
Also called conjugated bilirubin Called unconjugated bilirubin 
Water soluble Lipid soluble 
Excreted in urine Excreted by the biliary system 
Makes up less than 10% 
Makes up more than 90% of total 
bilirubin 
  
Levels of indirect bilirubin are raised in: 
• hemolysis 
• hematoma resolution 
• ineffective erythropoiesis 
• injury to muscles 
Levels of direct bilirubin are increased in: 
• hepatobiliary diseases 
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Conjugated hyperbilirubinemia cannot differentiate parenchymal liver 
disease from biliary obstruction. 
Serum bilirubin indicates prognosis in the following conditions: 
• liver cirrhosis 
• acute liver failure 
• primary biliary cirrhosis 
• alcoholic hepatitis 
It is incorporated into the MELD and Child Pugh scoring systems 
In long standing cholestasis, a fraction of conjugated bilirubin 
remains tightly bound to albumin which prevents its excretion in urine 
and this responsible for the persistence of hyperbilirubinemia inspite of 
cholestasis recovery. 
This is named the delta fraction. 
5.  BILE ACIDS 
Produced from cholesterol in the hepatocytes  
Not routinely used as a test of liver function. 
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Prognostic scores used in liver cirrhosis: 
1.Child Turcotte Pugh classification (CTP) 
2.Model for End stage Liver Disease(MELD) 
1. Child Turcotte Pugh score: (50) 
Predicts prognosis following surgery 
Initially designed to predict prognosis of patients about to undergo 
portosystemic shunt surgery due to liver disease. 
Also gives information about the frequency of complications 
occurring post-operatively like hepatic encephalopathy, intractable 
ascitis, renal failure, gastrointestinal bleeding and worsening of liver 
functions.  
 
        3-3.5           <3 >3 
 Child Pugh classes and 
Class A – well compensated cirrhosis:
• Moderate increase in surgical risk
Class B and C – decompensated cirrhosis:
• Substantial increase in surgical risk.
• Complications should be treated before elective surgery.
• In Child class C surgery must be done only in life threatening 
conditions eg. incarcerated hernia.
•  In patients undergoing surgery, meticulous care is essential. This 
includes:  
 Improvement in general nutritional status
48 
their surgical outcomes: (51, 52)
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 Hemodynamic stability maintenance 
 Broad spectrum antibiotic therapy 
 Coagulopathy correction 
 Avoiding nephrotoxins 
 Avoiding sedatives – to avoid precipitating hepatic encephalopathy 
2.Model for End stage Liver Disease(MELD): 
It is based on serum bilirubin, serum creatinine levels and INR 
values.  
It is used to allocate grafts for hepatic transplantation. 
Has many advantages over the CTP scoring system and used to 
predict early mortality following TIPS – transjugular intrahepatic 
portosystemic shunt. (53,54)  
 
Ranges between 6 and 40. 
 
 
 Advantages of MELD scoring system over CTP scoring:
• Variables in CTP lack reproducibility and consistency
• prone to subjective variations 
graded subjectively
• patients are classified only into three categories
• expected survival is not 
• patients with severe decompensation are not quantified.
MELD overcomes these problems and is a more reliable prognostic 
indicator. 
Additional tests : 
For assessment of liver function and severity of liver injury 
includes: 
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– ascitis, hepatic encephalopathy 
 
 
quantified 
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ULTRASOUND ELASTOGRAPHY: 
It makes use of the fact that the velocity of transmission of shear 
waves is altered by liver fibrosis (stiffness).   
The waves are created by a vibratory source. (55) 
The stiffness measured correlates with the stage of fibrosis of liver. 
(56) 
However difficult to use when patients are obese. (57) 
Values  >12.5 kPa indicate liver cirrhosis (58) 
However, fibrosis can be overestimated in those with extrahepatic 
cholestasis or acute liver injury. (59,60,61)  
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Quantitative tests of liver function: 
• Indocyanine green clearance 
• Galactose elimination capacity 
• Aminopyrine breath test 
• Antipyrine clearance 
• Monoethylglycinexylidide (MEGX) 
• Caffeine clearance 
However these tests have limitations including issues about: (62,63) 
• Cost 
• Availability 
• Lack of validity 
• Invasiveness 
LIVER BIOPSY 
Indicated for: 
• Finding the liver disease cause and for 
• Finding the extent of damage to the liver 
Pre-requisites: 
• INR value should not be greater than 3 after giving 10 mg of 
vitamin K by intramuscular route. 
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• Platelet count must be >50,000. 
Techniques: 
• Aspiration with Menghini needle 
• Transjugular liver biopsy 
• USG or CT guided biopsy 
• Tru cut needle biopsy 
Complications of biopsy: (73) 
• Pleurisy 
• Fibrinous perihepatitis 
• Haemorrhage 
• Intrahepatic hematomas 
• Haemobilia 
• Arteriovenous fistula 
• Biliary peritonitis 
• Puncturing of other organs 
• Infections  
  
54 
 
Percutaneous liver biopsy 
 
                             
Tru-cut biopsy needle 
 
 
Transjugular liver biopsy 
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SERUM CHOLINESTERASE 
Cholinesterases are basically enzymes that have been classified 
into two types by Mendel and Rudney as: 
• acetyl cholinesterase, otherwise called “true” cholinesterase  this 
is present in glial tissues and red blood cells. 
• serum or butryl or succinyl cholinesterase, otherwise called 
“pseudo” cholinesterase  which is synthesized by the liver. (16) 
Cholinesterases basically catalyze the hydrolysis of acetylcholine, 
which is a neurotransmitter, into acetic acid and choline.(30) 
 
This reaction is essential for the return of a cholinergic neuron to 
its resting state following its activation.(31) 
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ACETYL CHOLINESTERASE 
Acetylcholine(Ach) acts as a neurotransmitter at the nerve 
terminals. 
When an action potential reaches the nerve terminal Ach is 
released and acts on the post synaptic Ach receptor to result in 
transmission of nerve signal.  
Here, acetyl cholinesterase catalyzes Ach hydrolysis into choline 
and acetate thereby terminating the action of Ach. 
Acetyl cholinesterase occurs in a tetrameric G4 form mostly in the 
mammalian brain, and the amounts of the monomeric G1 form are much 
lesser.   
It is found in red blood cells , central and peripheral nervous 
system and in muscles. 
It has the following properties: (32) 
• high turnover 
• high affinity for acetylcholine 
• low affinity for non choline esters 
• gets inhibited when concentrations of acetylcholine are high.  
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SERUM CHOLINESTERASE (“pseudo” CHOLINESTERASE) 
It is an alpha glycoprotein with the following characteristics: 
• lower affinity for acetylcholine 
• high concentrations of acetylcholine do not inhibit it.(32)  
• half life is 12 days (33,34) 
• levels are raised in: 
  diabetes, 
 hyperthyroidism, 
 uremia, 
 hyperlipidemia. (35-37) 
• levels are lowered in: 
 protein energy malnutrition (38) 
 chronic liver damage and cirrhosis 
 European studies show that there is a prevalence of about 3-4% 
of congenital serum cholinesterase deficiency.(39) 
 Assessment of serum cholinesterase in various physiological and 
pathological conditions  
1. In protein energy malnutrition – eg. marasmus and kwashiorkor 
levels are low, however rise with nutritional rehabilitation.(40,41)   
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This is probably due to inadequate substrate availability rather than 
hepatic failure. (32) 
2. There was not any significant correlation between serum 
cholinesterase levels and old age in a study done by Lidia S et al. 
3. Levels were found to be low in patients with hepatic metastases 
even though other liver functions were normal.(43) 
This could be due to the anorexia accompanying malignancy. (44) 
Bozzeti et al. noted that levels of serum cholinesterase, body 
weight, thyroxin- binding prealbumin, transferrin, retinol binding protein 
and nitrogen balance increased following nutritional supplementation in 
patients with cancer. (45) 
4. Patients on hemodialysis are often malnourished and depleted of 
proteins, and as a result of the catabolic state values of serum 
cholinesterase and albumin were found to be low. (46) 
5. In severely burnt and critically ill patients values of serum 
cholinesterase were found to be reduced suggesting abnormal liver 
biosynthesis.(47) 
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6. In patients with anorexia nervosa, lower activity of serum 
cholinesterase  has been reported suggesting decreased nutrient 
availability. (48) 
7. In AIDS patient with an abnormal D-xylose test the values of 
serum cholinesterase, albumin and serum total proteins were found to be 
significantly lower than those who had normal D-xylose test. (49)      
ASSESSMENT OF SERUM CHOLINESTERASE LEVELS IN 
PATIENTS WITH LIVER DISEASES 
McArdle was the first to suggest that estimating serum 
cholinesterase was useful in distinguishing post hepatic from hepatic 
jaundice.(5)    
It originates from the liver and is associated with albumin synthesis 
closely. (17,18,19) 
Serum cholinesterase levels improve following successful liver 
transplant – thereby the origin of serum cholinesterase from the liver is 
confirmed. (20) 
It has also been observed that normalization of serum 
cholinesterase values may indicate the earliest point of recovery in liver 
injury. (21) 
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It is also found that in cases of extra-hepatic obstruction secondary 
to malignancies , the values of this enzyme are low probably due to either 
malnutrition or impaired liver function.(23,24,25) 
M.G. Khan noted in his study that estimation of serum 
cholinesterase was useful in both diagnosis and prognosis of cirrhosis of 
the liver. (26) 
Andrew Wilson et al observed that the serum cholinesterase levels 
in patients with liver disease was significantly different from the normal 
patients and those recovering from liver injury. 
They too reported that serum cholinesterase estimation was useful 
in confirming impairment of liver function and also as a prognostic 
indicator of liver function recovery 
Their studies also revealed that: 
• The values of this enzyme were normal in extrahepatic biliary 
obstruction which was of short duration and  
• values were low in attacks of cholangiohepatitis, malignant disease 
and prolonged extra hepatic obstructions.(27) 
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Hunt and Lehmann evaluated the role of estimating serum 
cholinesterase in the prediction of outcomes of portal venous shunt 
surgeries.(28)  
Apart from cirrhosis of liver, studies have suggested that 
estimating serum cholinesterase can also be useful in facilitating earlier 
diagnosis of non alcoholic fatty liver in patients with type 2 diabetes 
mellitus.(29) 
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MATERIALS AND METHODS 
 
SOURCE OF DATA: 
Patients who were admitted in the Institute of Internal Medicine, 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai-3 and diagnosed with liver cirrhosis, with fulfillment 
of the inclusion criteria and exclusion criteria were included in the study. 
SAMPLE SIZE: 100 
STUDY DESIGN: 
Hospital based observational study 
STUDY DURATION: 
6 months: March 2015 – August 2015 
INCLUSION CRITERIA: 
• Cases diagnosed with liver cirrhosis clinically and by 
ultrasonography. 
EXCLUSION CRITERIA   
• Organophosphate, carbamate poisoning 
• Exposure to succinyl choline, cocaine, codeine and morphine. 
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• Albumin or blood transfusion 4 weeks prior to enrolment in the 
study 
• History of or clinical evidence of UGI bleed at the time of 
enrolment in the study 
• Liver transplanted individuals    
DATA COLLECTION AND METHODS: 
Sampling method used was purposive. After selection, patients were 
subjected to thorough history taking and clinical examination. Following 
investigations were performed: 
• Liver function tests 
• Complete blood count 
• Renal function tests 
• Viral markers 
• PT INR 
• Ultrasonography of the abdomen 
• Serum cholinesterase  
ANALYSIS OF SERUM CHOLINESTERASE: 
The assay for serum cholinesterase was done using 
propionylthiocholine as substrate, by the kinetic propionylthiocholine 
method. 
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The reagents used included – propionylthiocholine, 2-nitrobenzoic 
acid, buffer and stabilizers. 
Cholinesterase caused the hydrolysis of propionylthiocholine to 
propionic acid and  thiocholine. This thiocholine reacted with 2-
nitrobenzoic acid to result in the formation of 5-thio-2-nitrobenzoic acid, 
which is yellow in colour. 
Fresh and non hemolysed serum was used for the assay. 
About 20 microliters of the sample was used with 1 ml of the 
reagent and the and the absorbance was first read at 15 seconds and then 
at 45 seconds and the results were calculated by the instrument 
automatically using the following formula: 
Activity in U/L = Absorbance/30 seconds × factor 
Factor = [TV×1000×2] ÷ [14.64 × SV × P] 
Where: 
TV= total reaction volume in ml 
SV= sample volume in ml 
14.64= millimolar absorption coefficient of 5-thio-2-nitrobenzoic acid at 
405 nm. 
P=cuvette pathlength in cm 
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2=conversion from absorbance/second to absorbance/minute.    
The normal values at 37 degree Celsius: 4900 – 11900 U/L. 
MELD SCORE - The calculator in the UNOS website was used to 
calculate MELD scores. 
Ascitis - detected clinically and by ultrasonography 
Hepatic encephalopathy- was graded clinically  
The correlation between the values of serum cholinesterase and the 
following variables was studied: 
• Serum albumin 
• Serum bilirubin 
• INR 
• Child Pugh score 
• MELD score 
STATISTICAL METHODS USED: 
The data was analysed using SPSS software. Pearsons correlation 
coefficient and p value were calculated to find the statistical significance. 
Variables were considered to be significant if p value <0.05.    
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Age Group
20-
31-
41-
51-
>60
Total
 
Most cases of cirrhosis (40 patients) occur in the 41 
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Table 1. AGE DISTRIBUTION 
 Frequency Percentage
30 6 6 
40 30 30
50 40 40
60 18 18
 6 6 
 100 100
– 
group (40%) 
 
30
40
18
6
31-40 41-50 51-60 >60
Age Distribution
 
 
 
 
 
 
50 years age  
 
100
Total
    
 
Among the 100 patients in our study, 80 patients
and 20 patients (20%) were females
 
Sex 
MALE 
FEMALE 
Total 
67 
 
Table 2. SEX DISTRIBUTION 
 
 (80%) were males 
 
 
 
80%
20%
SEX DISTRIBUTION
Frequency Percentage
80 80%
20 20%
100 100%
 
 
 
 
 
MALE
FEMALE
 
 
 
 
 Table 3. ETIOLOGY OF CIRRHOSIS
Etiology
Alcohol
Alcohol+HbSAg positive
Alcohol+HCV
HbSAg positive
HCV
Others
Total
The most common cause for cirrhosis among the patients in our study 
was alcohol, seen in 68 patients (68%).  
Alcohol Alcohol+HbSAg positive
68 
 
 Frequency Percentage
 68 
 3 
 2 
 6 
 2 
 19 
 100 
 
 
 
68%
3%
2%
6%
2%
19%
Etiology of Cirrhosis
Alcohol+HCV HbSAg positivec
 
 
68 
3 
2 
6 
2 
19 
100 
 
HCV Others
 Table 4. 
Ascites Severity
NO 
YES Mild
Total 
In our study 83 patients (83%) presented with ascitis, and among 
them 13 patients (13%) had severe (i.e. poorly controlled ascitis) and 70 
patients (70%) had mild 
 
NO
17%
69 
 
DISTRIBUTION OF ASCITIS
 Frequency 
17 
-Moderate 70 
83 Severe 13 
100 
 
 
– moderate (easily controlled ascitis).
 
YES
83%
DISTRIBUTION OF ASCITIS 
 
Percentage 
17 
83 
100 
 
 
Mild-
Moderate
70%
Severe
13%
 Table 5. DISTRIBUTION OF ICTERUS
In our study, 72 patients (72%) presented with icterus while the 
remaining patients did not have icterus clinically.
 
DISTRIBUTION OF PATIENTS WITH ICTERUS
No 
YES 
Total 
70 
 
 
 
28%
72%
No YES
Frequency Percentage
28 
72 
100 
 
 
 
28 
72 
100 
 Table 6. DISTRIBUTION OF HEPATIC ENCEPHALOPATHY
Present 
YES 
NO 
Total 
 
In our study, 31 patients (31%) presented with hepatic 
encephalopathy, of which 10 patients were in grade I (10%), 13 patients 
(13%) in grade II, 7 patients (7%) in grade III and 1 patient (1%) in grade 
IV.  
   
NO
69%
71 
Grade Frequency Percentage
Gr I 10 10
Gr II 13 13
Gr III 7 
Gr IV 1 
69 69
100 100
Gr I
10%
Gr II
13%
Gr III
7%
Gr IV
1%
YES
31%
Hepatic Encephalopathy
Gr I Gr II Gr III Gr IV NO
 
 
 
 
7 
1 
 
 
 
 Table 7. DISTRIBUTION OF SPLENOMEGALY
YES 
NO 
Total 
 
In our study, 37 patients (37%) had splenomegaly, as detected by 
ultrasonography. 
 
 
72 
 
Frequency Percentage
63 63 
37 37 
100 100
 
Distribution of Splenomegaly 
YES NO
 
 
 
 
  
 
 
In our study, 71 patients (71%) had bilrubin levels greater then 3 
mg/dl, 12 patients (12%) had bilirubin levels between 2 to 3 mg/dl and 17 
patients (17%) had bilirubin levels less than 2 mg/dl.   
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73 
Table 8. BILIRUBIN RANGE  
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12
<2 2 to 3
BILIRUBIN RANGE
Frequency
 Frequency Percentage
 17 17
 12 12
 71 71
 100 100
 
71
>3
  
 
 
 
 
      
In our study
patients (21%) had values between 1.7 
values >2.3 
6
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INR Range
<1.7 
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>2.3 
Total 
74 
Table 9. INR RANGE 
 
, 73 patients (73%) had INR levels less than 1.7, 21 
– 2.3 and 6 patients (6%) had 
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Frequency
 Frequency Percentage
73 
21 
6 
100 
 
 
73
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73 
21 
6 
100 
 Table 10. 
CPC 
A 
B 
C 
Total 
In our study, 41 patients (41%) belonged to Child Pugh class B, 35 
patients (35%) belonged to Child Pugh class C and 24 patients (24%) 
belonged to Child Pugh class A.
 
C
35%
75 
CHILD PUGH CLASS DISTRIBUTION
Frequency Percentage
24 24
41 41
35 35
100 100
 
 
 
A
24%
B
41%
CPC
 
 
 
 
 
 
 
 Table 11. 
MELD Range
<=15
>15
Total
 
         
In our study, 64 patients (64%) had MELD score greater 15 and 36 
patients (36%) had a MELD score less than or equal to 15.
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MELD SCORE DISTRIBUTION
 Frequency Percentage
 36 36
 64 64
 100 100
 
<=15
36%
>15
64%
MELD DISTRIBUTION
 
 
 
 
 
 
 
 Table 12. CORRELATION BETWEEN SERUM
AND SERUM CHOLINESTERASE
Se
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S.che Mean
>3.5 4360.269231
3-3.5 2531.509434
<3 2155.619048
In our study, serum albumin levels were compared with the serum 
cholinesterase levels. It was found that the serum cholinesterase levels 
were lower in patients with lower values of serum albumin (positively 
correlated) which was statistically significant w
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 Min Max Std Range Correlation
 1437 6101 1053.098 4664 
0.52124 1237 5125 815.0791 3888 
 1437 4800 756.957 3363 
 
ith p – value < 0.01.  
>3.5 3-3.5
Serum Albumin
 ALBUMIN 
 
 
P 
Value 
 
 <0.01 
 
 
<3
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Table 13. Correlation between Serum Bilirubin and Serum 
Cholinesterase 
 
Bilirubin 
Range Frequency Percentage 
<2 17 17 
2 to 3 12 12 
>3 71 71 
Total 100 100 
 
 
  Serum Cholinesterase     
Bilirubin 
Range Mean Min Max Range Correlation 
P 
Value 
<2 
    
4567.2353 2131 
 
6101   3970 
-0.675 <0.01 2 to 3 
    
4361.4167 2963 
 
5318   2355 
>3 
   
2293.3099 1237 
 
4396   3159 
 
  
  
 
In our study, serum bilirubin levels were negatively correlated with 
serum cholinesterase levels and the p value was <0.01 % which was 
statistically significant.
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Table 14. CORRELATION BETWEEN INR (INTERNATIONAL 
NORMALISED RATIO) AND SERUM CHOLINESTERASE 
INR Range Frequency Percentage 
<1.7 73 73 
1.7-2.3 21 21 
>2.3 6 6 
Total 100 100 
  Serum Cholinesterase     
INR Range Mean Min Max Range Correlation P Value 
<1.7 3297.438 1237  6101  4864 
   -0.49565 <0.01 1.7-2.3 1998.286 1437  4296 2859 
>2.3 1688 1356  1967 611 
 
 
In our study, it was found that INR value was negatively correlated 
with the values of serum cholinesterase and it was statistically significant 
with p value  <0.01. 
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Table 15. CORRELATION BETWEEN CHILD PUGH CLASS 
AND SERUM CHOLINESTERASE 
  Serum Cholinesterase   Correlation P Value 
CPC  Mean Min Max Range 
-0.850087 <0.01 
A 4692.25   3845   6101 2256 
B 2779.682927   1852   4800 2948 
C 1892.114286   1237   2649 1412 
 
 
In our study, it was found that serum cholinesterase values were 
higher among Child Pugh class A patients than class B patients, in whom 
the values of serum cholinesterase were higher than class C patients. 
Thus, higher Child Pugh grading correlated negatively with the serum 
cholinesterase values and it was statistically significant with p value 
<0.01      
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Table 16. CORRELATION BETWEEN MELD SCORE AND 
SERUM CHOLINESTERASE 
 
 
In our study, it was found that MELD scores were inversely 
correlated with the serum cholinesterase levels and it was statistically 
significant p value <0.01. 
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Serum Cholinesterase 
  
MELD Score Mean Min Max Range Correlation P Value 
<=15 4304.833 2131 6101 3970 
-0.7927219 <0.01 
>15 2153.609 1237 3125 1888 
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DISCUSSION 
Our study was conducted to estimate the levels of serum 
cholinesterase among patients with liver cirrhosis and compare its level 
with other tests of liver function like serum albumin, serum bilirubin, PT 
INR and compare it with MELD and Child Pugh scores. 
Our study population consisted of 100 patients who were 
diagnosed with cirrhosis of liver either by ultrasonography or clinically. 
Serum cholinesterase levels were measured in all the 100 patients along 
with routinely performed tests like serum bilirubin, serum albumin, PT 
INR, serum creatinine. 
Analysis was done to study the correlation between levels of serum 
cholinesterase and levels of serum albumin, serum bilirubin, INR and 
severity of cirrhosis of liver using Pearson’s correlation coefficient. 
Following observations were made from our study.  
Age distribution: 
Out of 100 patients, majority were in the 41 – 50 years age group 
(40%) . This showed that cirrhosis is most commonly seen in the middle 
age. 
 
84 
 
Sex distribution: 
Out of 100 patients, 80 patients were males (80%) and the 
remaining 20 patients (20%) were females. The male to female ratio is 
4:1. 
Etiology 
Among 100 patients with liver cirrhosis, the most common 
etiological cause for cirrhosis was alcohol in 68 patients (68%) followed 
by other causes in 19 patients (19%).   
Clinical signs: 
Out of the 100 patients in the study, 83 patients (83%) had ascitis, 
72 patients (72%) had icterus,63 patients (63%) had splenomegaly and 31 
patients (31%)  had hepatic encephalopathy. 
Among patients with ascitis, 70 patients (70%) had mild – 
moderate (medically controlled) ascitis and the remaining 13% had 
severe ascitis (medically refractory) 
Among the 31 patients with hepatic encephalopathy, 10 patients 
(10%) had grade I, 13 patients (13%) had grade II, 7 patients (7%) had 
grade III, 1 patient (1%) had grade IV hepatic encephalopathy.   
85 
 
Among the 100 patients, 63 patients (63%) had splenomegaly 
which was indicative of the presence of portal hypertension.   
Bilirubin levels: 
Among the 100 patients, 71 patients (71%) had a bilirubin level 
greater than 3 mg/dl and 12 patients (12%) had bilirubin levels between 2 
to 3. A bilirubin level equal to or greater than 3 can be detected clinically 
as scleral icterus.  
Coagulopathy:  
In our study, 73 patients (73%) had INR levels less than 1.7. Thus 
the majority of patients in our study did not have coagulopathy.    
Child-Pugh class: 
In our study, out of 100 patients, 41 patients (41%) belonged to 
class B, 35 patients (35%) to class C and 24 patients (24%) belonged to 
class A. Thus the majority of patients belonged to class B. Child-Pugh 
class is used in the assessment of patients for liver transplantation and is 
good indicator of liver disease severity.   
MELD score: 
In our study, 64 patients (64%) had MELD score greater than 15 
and 36 patients (36%) had MELD score less than or equal to 15. MELD 
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score predicts the prognosis of patients with portal hypertension and liver 
disease and used for forming the priority list for liver transplant.   
CORRELATION BETWEEN SERUM ALBUMIN AND SERUM 
CHOLINESTERASE 
In our study the correlation between serum albumin levels and the 
levels of serum cholinesterase was studied. It was found that they were 
positively correlated with a p value <0.01 This was comparable with the 
observations in the study by Jeyamani Ramachandran et al and Fanping 
Meng et al.  
CORRELATION BETWEEN SERUM BILIRUBIN AND SERUM 
CHOLINESTERASE 
In our study, it was found that the serum bilirubin levels were 
negatively correlated with serum cholinesterase levels and the p value 
was <0.01 which was statistically significant. This is similar to the 
observations made in the study by  Jeyamani Ramachandran et al. 
CORRELATION BETWEEN INR LEVELS AND SERUM 
CHOLINESTERASE 
In our study, it was found that INR value was negatively correlated 
with the values of serum cholinesterase and it was statistically significant 
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with p value  <0.01. This was comparable to the observations made in the 
studies by  Jeyamani Ramachandran et al and Fanping Meng et al. 
CORRELATION BETWEEN CHILD PUGH CLASS AND SERUM 
CHOLINESTERASE 
In our study, it was found that the serum cholinesterase values were 
lower in patients with Child Pugh class C and B compared to those with 
Child Pugh class C. This was found to be statistically significant with a p 
value <0.01. This was similar to the observations made in the study by 
Fanping Meng et al and M.H.Sleisenger et al who noted in their study 
that values of serum cholinesterase were lower among patients with 
decompensated cirrhosis then patients with compensated cirrhosis . 
CORRELATION BETWEEN MELD SCORE AND SERUM 
CHOLINESTERASE 
In our study, it was found that MELD scores were inversely 
correlated with the seum cholinesterase levels and it was statistically 
significant with  p value <0.01. It was similar to the findings noted by 
Jeyamani Ramachandran et al. 
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CONCLUSION 
From our study, the following results were concluded: 
 Liver cirrhosis was more commonly seen among middle aged 
adults (5 th decade) and is much more common in males with a 
male to female ratio of 4:1. 
 The most commonly observed etiology of cirrhosis was alcohol. 
 The most common presenting symptom was ascitis, and the second 
most common symptom was icterus. 
 Among patients with ascitis, majority had ascitis which was mild – 
moderate (medically controlled). 
 Majority of patients in the study did not have hepatic 
encephalopathy. 
 Among patients with hepatic encephalopathy, most patients were in 
grade II hepatic encephalopathy. 
 Majority of patients had splenomegaly either clinically or 
ultrasonographically, which was indicative of portal hypertension. 
 Majority of patients had bilirubin levels greater than 3 mg/dl. 
 Most patients in the study did not have coagulopathy, and had INR 
level <1.7. 
 Majority of the patients belonged to Child Pugh class B. 
 Most patients had a MELD score greater than 15. 
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 There was significant positive correlation between serum albumin 
and serum cholinesterase levels. Patients with a lower serum 
albumin level also had a lower serum cholinesterase level.  
 Significant negative correlation was noted between serum bilirubin 
and serum cholinesterase levels. Patients with a higher serum 
bilirubin level had a lower serum cholinesterase level. 
 There was significant negative correlation between INR levels and 
serum cholinesterase levels. Patients in coagulopathy had a lower 
serum cholinesterase level. 
 Significant correlation was found between serum cholinesterase 
levels and the severity of liver cirrhosis. Its levels were lower in 
patients with more severe liver disease. Levels were lowest among 
Child – Pugh class C patients. 
 There was significant correlation between serum cholinesterase 
levels and MELD scores. Patients with a higher MELD score had a 
lower serum cholinesterase level. 
Thus, there was significant correlation between levels of serum 
cholinesterase and severity of liver cirrhosis.    
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SUMMARY 
The estimation of serum cholinesterase levels has several 
implications in the assessment and management of patients with cirrhosis 
of liver. 
Serum cholinesterase activity levels have shown good correlation 
with the other routinely performed tests of liver function. 
Its assessment proves to be even more useful in settings were the 
commonly performed tests of liver function show abnormal results or 
altered values secondary to non hepatic causes. 
It’s a relatively inexpensive test and can be easily measured on a 
outpatient basis and among inpatients. 
Not only is it useful in the diagnosis, but its value is altered 
according to the liver disease severity which helps assess prognosis and 
further management.  
Hence, estimation of serum cholinesterase routinely will prove 
useful in the diagnosis and management of liver cirrhosis.  
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ANNEXURES 
  
PROFORMA 
PATIENT DETAILS: 
Name:     Age:   Sex:   
IP No. : 
ON ADMISSION: 
Main Complaints :  
o H/o jaundice           
o H/o abdominal distension           
o H/o pedal oedema 
o H/o reduced urine output 
o H/o breathlessness 
o H/o orthopnoea/PND 
o H/o haemetemesis 
o H/o melena 
o H/o  seizures 
o H/o altered sensorium 
o H/o altered sleep pattern 
o H/o chest pain 
o H/o abdominal pain 
o H/o fever 
o H/o constipation            
o H/o intake of any drugs 
Co – Morbid Illness : 
Significant Past History : 
 
CLINICAL EXAMINATION: 
Pulse  :     BP : 
RR  :     Temp : 
Pallor  :     Icterus : 
CVS   :     RS : 
P/A  : 
CNS : 
 
INVESTIGATIONS : 
Hemogram   : 
Renal Function Test  : 
BT/CT/PT/INR   : 
Blood Grouping   : 
Serum cholinesterase  : 
ECG    : 
CXR    : 
USG Abdomen   : 
LFT    :     
 
  
 
 
 
INFORMATION SHEET 
 
 We are conducting a study on “A STUDY ON SERUM 
CHOLINESTERASE AS A BIOMARKER OF LIVER CIRRHOSIS” 
among patients attending Rajiv Gandhi Government General Hospital, Chennai 
and for that your specimen may be valuable to us. 
 
The purpose of this study is 
1. To estimate the level of serum cholinesterase in patients with liver 
cirrhosis. 
2. To compare its level with other tests of liver function like bilirubin, 
SGOT,SGPT,PT INR,ALP and MELD Score. 
We are selecting certain cases and if you are found eligible, we may be 
using your information which in any way do not affect your final report or 
management. 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
Signature of Investigator                       Signature of Participant 
 
Date: 
Place: 
 
  
  
 
 
 
PATIENT CONSENT FORM 
Study Details : “A STUDY ON SERUM CHOLINESTERASE AS A     
    BIOMARKER OF LIVER CIRRHOSIS” 
Study Centre : RAJIV GANDHI GOVERNMENT GENERAL HOSPITAL,  
   CHENNAI. 
Patient’s Name: 
Patient’s Age: 
In Patient Number: 
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above study. I have the opportunity to 
ask question and all my questions and doubts have been answered to my complete satisfaction. ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at any time 
without giving reason, without my legal rights being affected. ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the ethical 
committee and the regulatory authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be conducted in relation to it, even 
if I withdraw from the study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. ❏ 
I agree to take part in the above study and to comply with the instructions given during the study and 
faithfully cooperate with the study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or well being or any unexpected or unusual symptoms. ❏ 
I hereby consent to participate in this study 
 
❏ 
 
I hereby give permission to undergo complete clinical examination and diagnostic tests including 
hematological, biochemical, radiological tests. 
❏ 
 
Signature/Thumb Impression                                      Signature of Investigator 
Patient’s Name & Address:    Study Investigator’s Name: 
            Dr.SUJATHA.N. 
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1 44 M + + ++ Gr II 8.7 3.3 1.5 32/2.98 HbSAg +ve Ci+As+S C 31 1967 
2 47 M + + + - 11.4 3 0.5 13.2/1.18 HbSAg +ve Ci+As+S B 17 3125 
3 33 M + + + - 5.2 3.2 0.7 20.7/1.8 - Ci+As C 19 2242 
4 50 M + + + Gr I  3.3 3 2.8 29.6/2.51 - Ci+As+S C 31 1356 
5 45 F - - + - 1 3 1.5 14.2/1.31 - Ci+As+S B 13 4372 
6 45 M + + ++ Gr I 28.3 2.8 1.7 25.2/2.16 HbSAg +ve Ci+As+S C 33 1635 
7 38 M + + + - 11.5 3.5 1.3 30.2/2.56 - Ci+As+S C 29 1435 
8 40 M + + + Gr I 17.5 2.9 0.6 21.3/1.89 HCV +ve Ci+As+S C 24 1532 
9 42 M - - + Gr III 10.6 2.2 1.1 19.3/1.45 HCV +ve Ci+As+S C 20 1634 
10 60 M + + + Gr I 5.6 2.6 1.6 24.1/2.07 - Ci+As+S C 26 1463 
11 55 F - - + - 1.8 1.8 1.3 13.8/1.3 - Ci+As+S B 14 2131 
12 55 F - - + - 0.4 2.7 0.7 13.7/1.23 - Ci+As B 9 4800 
13 55 M + + + Gr I 8.9 2 1.2 13.4/1.14 - Ci+As C 18 2131 
14 52 M + + + - 3.2 3 0.5 13.7/1.16 - Ci+As B 12 4363 
15 52 M + + + - 3.8 2.5 0.9 29.8/2.53 - Ci+As+S C 22 1962 
16 36 M + - - - 1.7 3.6 0.8 11.2/1 - Ci A 8 6101 
17 28 M + - + - 2.9 2.9 1.4 13.6/1.2 - Ci+As+S B 16 2963 
18 33 M + + + Gr III 16 3.2 1.1 25.3/2.1 - Ci+As+S C 26 2243 
19 27 M + - - - 1.8 3.3 0.5 11.5/1.0 - Ci A 9 5125 
20 45 M + + + - 5 3.6 1.7 12.6/1.1 - Ci+As+S B 19 2563 
21 45 M + + - - 11 3.1 1 25.3/2.2 - Ci+S B 24 2869 
22 56 M + - + - 2.8 2.9 1.6 11.2/1 - Ci+As B 15 3100 
23 70 M - + ++ - 12.4 3.1 1.3 13.8/1.3 HbSAg  +ve Ci+As+S C 21 2649 
24 43 M + - - - 2.7 3.8 0.6 13.9/1.2 - Ci A 12 3964 
25 44 F - + + Gr I 7.5 2.6 1.1 13.7/1.2 HbSAg +ve Ci+As+S C 17 2436 
26 29 M + + + - 6.3 3 0.9 11.5/1 - Ci+As B 13 4396 
27 46 F - + + - 8 3.1 0.8 13.6/1.2 HbSAg +ve Ci+As+S B 16 2865 
28 57 M + + ++ Gr II 5.8 3.4 1.3 25.7/2.2 - Ci+As+S C 24 1934 
29 63 M + + + - 6.7 3.6 1.1 26.4/2.2 - Ci+As+S B 23 1923 
30 49 M - + - - 3 3.6 0.5 14.16/1.2 - Ci+S A 13 5318 
31 35 M + + + - 8.6 3.2 1.3 12.5/1 - Ci+As+S B 17 2676 
32 46 M - + + - 9.4 3.1 1.1 11.6/1 - Ci+As B 16 2789 
33 53 M + + ++ Gr II 12.6 2.9 0.9 13.7/1.2 - Ci+As+S C 18 2345 
34 55 F - + - - 5.4 3.2 1.1 25/2.1 - Ci+S B 22 1852 
35 34 M + - - - 2.3 3.6 0.9 13.8/1.2 - Ci A 12 5232 
36 60 M + + + - 6.3 3.3 1.5 11.4/1 - Ci+As B 17 2345 
37 57 M + + + - 7.3 3.2 1.2 12.3/1.1 - Ci+As B 17 2652 
38 45 M + + ++ Gr III 10.3 2.8 1.4 28/2.5 - Ci+As+S C 29 1754 
39 38 M + + + - 4.2 3.6 1.1 12.5/1 - Ci+As B 13 4312 
40 41 F - - + - 1.7 3.6 0.6 18.4/1.6 HbSAg +ve Ci A 14 5324 
 41 33 M + + + - 6.3 3.4 0.9 14.5/1.3 - Ci+As+S B 16 2489 
42 39 M + + + Gr III 10.5 3.3 1.1 11.8/1.1 - Ci+As+S C 17 1237 
43 46 M + + + - 8.5 3.2 1.3 12.4/1.1 - Ci+As+S B 18 2229 
44 29 M + - - - 1.4 3.8 0.7 23.2/2 - Ci A 15 4296 
45 47 M - + + Gr II 8 3.6 1.1 25.2/2.16 - Ci+As+S C 24 1437 
46 36 M - + + - 6 3.2 1.5 11.8/1.1 
HbSAg  
+ve Ci+As+S B 18 2134 
47 38 M + + + - 7.6 3.4 1 12.7/1.2 - Ci+As B 16 2735 
48 47 F - - + - 1.8 3.6 0.6 17.25/1.5 - Ci+As A 13 4376 
49 37 M + + + - 5.7 3.2 0.7 13.8/1.3 - Ci+As+S B 16 2536 
50 35 M + - + - 1.9 3.7 0.7 12.76/1.1 - Ci A 10 5103 
51 49 F - + - - 4.3 3.2 0.6 12.6/1.1 - Ci+S B 13 3963 
52 48 M + + ++ Gr II 12 3.4 0.9 23.5/2 - Ci+As+S C 24 1869 
53 60 F + + + - 10 3.1 0.6 14/1.2 - Ci+S B 17 2106 
54 54 M + + + Gr III 13.6 2.8 1.4 25.7/2.2 - Ci+As+S C 28 1684 
55 36 M + - - - 2.3 3.6 1 11.6/1 - Ci+S A 10 5132 
56 47 F - + + - 6.3 3.4 0.9 11.5/1.1 HCV+ve Ci+As B 14 2753 
57 38 M + + ++ Gr II 6.5 2.9 0.8 18.9/1.7 - Ci+As+S C 19 1437 
58 47 M + + + - 7.5 3.2 1.1 15/1.2 HCV+ve Ci+As+S B 18 1988 
59 39 M - + + - 6.1 3.4 1 14/1.1 - Ci+As B 14 2768 
60 57 M + - - - 2.9 3.6 0.9 11.5/1 - Ci+S A 10 4239 
61 34 M + + + - 7.1 3.2 0.8 11.7/1.2 - Ci+As+S B 16 2346 
62 36 M + - + - 1.8 3.6 0.7 12.7/1.1 - Ci+As+S A 10 5234 
63 45 M + + + Gr II 5.8 3.1 1.1 21/1.9 - Ci+As+S C 21 1534 
64 42 M + + + - 8.2 3.4 1.2 11.6/1.1 - Ci+As B 17 2238 
65 31 M + - + - 1.9 3.6 0.9 11.7/1 - Ci+As A 9 4201 
66 43 M - + + Gr II 11.3 2.9 1.3 26/2.2 - Ci+As+S C 27 1932 
67 46 M + + + - 10.3 3.2 1.1 14/1.2 - Ci+As+S B 18 2121 
68 43 M + - + - 1.8 3.8 0.5 13.8/1.2 - Ci+As+S A 11 4003 
69 52 M + + + - 6.4 3.1 1 13/1.3 - Ci+As B 16 2459 
70 37 M + + + Gr I 11.2 3.2 0.9 23.5/2 - Ci+As+S C 23 2101 
71 47 F - - - - 2.9 3.6 0.8 11.5/1.1 - Ci A 12 4126 
72 70 M + + + - 6.5 3.3 1.1 11.4/1 - Ci+As B 14 2963 
73 62 F - + + Gr II 13.2 3.1 1.1 19/1.6 - Ci+As+S C 22 2411 
74 46 M + + - - 3 3.7 0.8 11.7/1.1 - Ci A 12 3925 
75 53 F - + + - 7.2 3.3 0.9 12.5/1.2 - Ci+As B 16 2452 
76 29 M + - + - 1.8 3.7 0.8 11.3/1 - Ci+As A 9 3845 
77 32 M + + + Gr III 10.2 2.9 1.1 24/2.1 - Ci+As+S C 24 2430 
78 47 M + + + - 7.6 3.1 1.2 12.1/1 - Ci+As B 16 2639 
79 43 M + - + - 1.5 3.6 0.5 16.5/1.5 - Ci+S A 13 4631 
80 35 M + + ++ Gr IV 10.3 2.9 1.6 26/2.3 - Ci+As+S C 29 1943 
 
 
 
 81 21 M + + + - 6.4 3.2 1.1 13.5/1.2 - Ci+As+S B 16 2766 
82 43 M + - - - 2.8 3.6 0.9 12.7/1.1 - Ci A 11 4765 
83 36 M + + + - 8.7 3.1 1 12.8/1.1 - Ci+As+S B 16 2836 
84 38 F - - + - 1.9 3.6 0.7 11.4/1 - Ci+As+S A 9 4396 
85 62 F - + ++ Gr II 4.5 3 0.9 19/1.6 HbSAg +ve Ci+As+S C 17 1923 
86 50 M + + + - 11.5 3.3 1.2 16.3/1.4 - Ci+As B 21 1981 
87 46 M + + + - 6.3 3.4 1.1 11.8/1.2 - Ci+As+S B 16 2896 
88 47 F - + + - 5.4 3.1 0.8 11.6/1.1 - Ci+As+S B 14 2439 
89 34 M + - - - 1.2 3.4 0.8 16.5/1.5 - Ci+S A 12 4357 
90 37 M - + ++ Gr II 14 2.9 1.6 20.1/1.7 - Ci+As+S C 27 1845 
91 32 M + + ++ Gr I 13 2.9 1.2 11.6/1.01 - Ci+As+S C 18 2348 
92 46 M + - + - 1.8 3.6 0.7 17.8/1.4 - Ci+As+S A 12 5348 
93 41 M + + + Gr II 16 3.2 1.1 16.3/1.4 - Ci+As+S C 22 1863 
94 46 F - - - - 2.3 3.6 0.8 11.4/1 - Ci A 10 4638 
95 43 M + + ++ Gr III 10.6 3.4 1.6 28.3/2.4 - Ci+As+S C 30 1654 
96 55 F + + + Gr I 12.4 3.2 1.1 11.5/1 - Ci+As C 17 1932 
97 32 M + + + Gr I 16 3.2 1.1 17/1.5 - Ci+As+S C 22 2163 
98 36 M + - - - 2.8 3.6 0.7 12.8/1.1 - Ci A 11 4935 
99 61 F - + + Gr II 11.4 2.9 1.4 21.8/1.8 - Ci+As+S C 25 1763 
100 42 M + + + - 10.5 3.1 1 19.2/1.6 - Ci+As B 21 2034 
 
M- Male; F-Female; Under Ascitis: + mild moderate, ++ severe ascitis; Gr-
Grade 
Ci- Cirrhosis; As-Ascitis; S- Splenomegaly; PT INR- Prothrombin 
Time/International Normalised Ratio; MELD-Model for End stage Liver 
Disease;  
 
 
 
 
 
 
  
 
  
 
